AI-designed drug
AI-Designed Drug AH-001 Completes U.S. Phase I Trial, Demonstrating Excellent Safety and Tolerability
AH-001; AI-designed drug; Phase I clinical trial; safety; tolerability; androgenetic alopecia; protein degrader; AnHorn Medicines; generative AI; hair loss
Iambic’s AI-Designed HER2 Inhibitor IAM1363 Shows Early Anti-Tumor Activity in Heavily Pretreated Patients
Iambic Therapeutics; AI-designed drug; IAM1363; HER2 inhibitor; cancer; clinical trial; Phase 1/1b; ESMO 2025; brain-penetrant; tyrosine kinase inhibitor